Page last updated: 2024-12-08

3-(9-acridinylamino)-5-hydroxymethylaniline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-(9-acridinylamino)-5-hydroxymethylaniline: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID380482
CHEMBL ID321473
SCHEMBL ID1865418
MeSH IDM0440119

Synonyms (17)

Synonym
NCI60_022917
nsc666097
[3-(acridin-9-ylamino)-5-amino-phenyl]methanol
(3-(9-acridinylamino)-5-aminophenyl)methanol hydrochloride
[3-(acridin-9-ylamino)-5-aminophenyl]methanol
CHEMBL321473 ,
154310-42-6
[3-(acridine-9-yl-amino)-5-aminophenyl]-methanol
3-(9-acridinylamino)-5-hydroxymethylaniline
GZHHMAFXYHPHBO-UHFFFAOYSA-N
3-(9-acridinylamino)-5-(hydroxymethyl)aniline
3-(acridin-9-yl)amino-5-hydroxymethylaniline
SCHEMBL1865418
DTXSID30327555
(3-(acridin-9-ylamino)-5-aminophenyl)methanol
bdbm50470357
PD181002
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA topoisomerase 2-alphaHomo sapiens (human)IC50 (µMol)1.00000.48004.35649.9400AID57198
DNA topoisomerase 2-betaHomo sapiens (human)IC50 (µMol)1.00000.03002.77167.8000AID57198
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (24)

Processvia Protein(s)Taxonomy
hematopoietic progenitor cell differentiationDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topological changeDNA topoisomerase 2-alphaHomo sapiens (human)
DNA ligationDNA topoisomerase 2-alphaHomo sapiens (human)
DNA damage responseDNA topoisomerase 2-alphaHomo sapiens (human)
chromosome segregationDNA topoisomerase 2-alphaHomo sapiens (human)
female meiotic nuclear divisionDNA topoisomerase 2-alphaHomo sapiens (human)
apoptotic chromosome condensationDNA topoisomerase 2-alphaHomo sapiens (human)
embryonic cleavageDNA topoisomerase 2-alphaHomo sapiens (human)
regulation of circadian rhythmDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of apoptotic processDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of single stranded viral RNA replication via double stranded DNA intermediateDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIDNA topoisomerase 2-alphaHomo sapiens (human)
rhythmic processDNA topoisomerase 2-alphaHomo sapiens (human)
negative regulation of DNA duplex unwindingDNA topoisomerase 2-alphaHomo sapiens (human)
resolution of meiotic recombination intermediatesDNA topoisomerase 2-alphaHomo sapiens (human)
sister chromatid segregationDNA topoisomerase 2-alphaHomo sapiens (human)
neuron migrationDNA topoisomerase 2-betaHomo sapiens (human)
DNA topological changeDNA topoisomerase 2-betaHomo sapiens (human)
axonogenesisDNA topoisomerase 2-betaHomo sapiens (human)
B cell differentiationDNA topoisomerase 2-betaHomo sapiens (human)
forebrain developmentDNA topoisomerase 2-betaHomo sapiens (human)
positive regulation of single stranded viral RNA replication via double stranded DNA intermediateDNA topoisomerase 2-betaHomo sapiens (human)
cellular response to hydrogen peroxideDNA topoisomerase 2-betaHomo sapiens (human)
cellular response to ATPDNA topoisomerase 2-betaHomo sapiens (human)
cellular senescenceDNA topoisomerase 2-betaHomo sapiens (human)
positive regulation of double-strand break repair via nonhomologous end joiningDNA topoisomerase 2-betaHomo sapiens (human)
sister chromatid segregationDNA topoisomerase 2-betaHomo sapiens (human)
resolution of meiotic recombination intermediatesDNA topoisomerase 2-betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
magnesium ion bindingDNA topoisomerase 2-alphaHomo sapiens (human)
DNA bindingDNA topoisomerase 2-alphaHomo sapiens (human)
chromatin bindingDNA topoisomerase 2-alphaHomo sapiens (human)
RNA bindingDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA topoisomerase 2-alphaHomo sapiens (human)
protein kinase C bindingDNA topoisomerase 2-alphaHomo sapiens (human)
protein bindingDNA topoisomerase 2-alphaHomo sapiens (human)
ATP bindingDNA topoisomerase 2-alphaHomo sapiens (human)
ATP-dependent activity, acting on DNADNA topoisomerase 2-alphaHomo sapiens (human)
DNA binding, bendingDNA topoisomerase 2-alphaHomo sapiens (human)
protein homodimerization activityDNA topoisomerase 2-alphaHomo sapiens (human)
ubiquitin bindingDNA topoisomerase 2-alphaHomo sapiens (human)
protein heterodimerization activityDNA topoisomerase 2-alphaHomo sapiens (human)
DNA bindingDNA topoisomerase 2-betaHomo sapiens (human)
chromatin bindingDNA topoisomerase 2-betaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA topoisomerase 2-betaHomo sapiens (human)
protein bindingDNA topoisomerase 2-betaHomo sapiens (human)
ATP bindingDNA topoisomerase 2-betaHomo sapiens (human)
ribonucleoprotein complex bindingDNA topoisomerase 2-betaHomo sapiens (human)
metal ion bindingDNA topoisomerase 2-betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
nucleolusDNA topoisomerase 2-alphaHomo sapiens (human)
nuclear chromosomeDNA topoisomerase 2-alphaHomo sapiens (human)
centrioleDNA topoisomerase 2-alphaHomo sapiens (human)
chromosome, centromeric regionDNA topoisomerase 2-alphaHomo sapiens (human)
condensed chromosomeDNA topoisomerase 2-alphaHomo sapiens (human)
male germ cell nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleoplasmDNA topoisomerase 2-alphaHomo sapiens (human)
nucleolusDNA topoisomerase 2-alphaHomo sapiens (human)
cytoplasmDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complexDNA topoisomerase 2-alphaHomo sapiens (human)
protein-containing complexDNA topoisomerase 2-alphaHomo sapiens (human)
ribonucleoprotein complexDNA topoisomerase 2-alphaHomo sapiens (human)
nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleolusDNA topoisomerase 2-betaHomo sapiens (human)
heterochromatinDNA topoisomerase 2-betaHomo sapiens (human)
nucleusDNA topoisomerase 2-betaHomo sapiens (human)
nucleoplasmDNA topoisomerase 2-betaHomo sapiens (human)
nucleolusDNA topoisomerase 2-betaHomo sapiens (human)
cytosolDNA topoisomerase 2-betaHomo sapiens (human)
ribonucleoprotein complexDNA topoisomerase 2-betaHomo sapiens (human)
nucleusDNA topoisomerase 2-betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (62)

Assay IDTitleYearJournalArticle
AID123408In vitro anticancer activity against 5 B6D2F-1 mice bearing P388 leukemia measured by the toxicity death at an intravenous dose of 16(mg/kg).. 1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID111057In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 1 at an intravenous dose of 16(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID111062In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 1 at an intravenous dose of 30(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID266296Antiproliferative activity against human CCRF-CEM cell line2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Potent antitumor 9-anilinoacridines and acridines bearing an alkylating N-mustard residue on the acridine chromophore: synthesis and biological activity.
AID116324In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the increase in lifespan at an intravenous dose of 22(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID81631In vitro cytotoxicity against human leukemic HL-60 cell line.1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships.
AID53599Cytotoxicity against human Glioblastoma multiformi DBTRG2002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Antitumor AHMA linked to DNA minor groove binding agents: synthesis and biological evaluation.
AID320265Displacement of ethidium bromide from calf thymus DNA2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Synthesis, cytotoxic evaluation, and DNA binding of novel thiazolo[5,4-b]quinoline derivatives.
AID266301Antiproliferative activity against human MX1 cell line2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Potent antitumor 9-anilinoacridines and acridines bearing an alkylating N-mustard residue on the acridine chromophore: synthesis and biological activity.
AID367776Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Novel DNA-directed alkylating agents: design, synthesis and potent antitumor effect of phenyl N-mustard-9-anilinoacridine conjugates via a carbamate or carbonate linker.
AID111071In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 11 at an intravenous dose of 16(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID266300Antiproliferative activity against human HCT116 cell line2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Potent antitumor 9-anilinoacridines and acridines bearing an alkylating N-mustard residue on the acridine chromophore: synthesis and biological activity.
AID55287Percentage of protein-linked DNA breaks; Not determined2002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Antitumor AHMA linked to DNA minor groove binding agents: synthesis and biological evaluation.
AID53600The compound was tested for the cytotoxicity DC-3F cell lines1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships.
AID85751Cytotoxicity against human colon HT-29 cell line2002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Antitumor AHMA linked to DNA minor groove binding agents: synthesis and biological evaluation.
AID367772Cytotoxicity against vinblastine-resistant human CCRF-CEM cells after 72 hrs by XTT assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Novel DNA-directed alkylating agents: design, synthesis and potent antitumor effect of phenyl N-mustard-9-anilinoacridine conjugates via a carbamate or carbonate linker.
AID111213In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 7 at an intravenous dose of 30(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID81469In vitro inhibition of human leukemic HL-60 cell growth in culture1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID248840Concentration required for growth inhibition of vinblastine resistant human lymphoblastic leukemic cell line (CCRF-CEM/VBL) was determined2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation.
AID367774Ratio of IC50 for vinblastine-resistant human CCRF-CEM cells to IC50 for human CCRF-CEM cells2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Novel DNA-directed alkylating agents: design, synthesis and potent antitumor effect of phenyl N-mustard-9-anilinoacridine conjugates via a carbamate or carbonate linker.
AID110721In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the Average survival time(days) at an intravenous dose of 30(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID111077In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 7 at an intravenous dose of 16(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID248807Concentration required for growth inhibition of taxol resistant human lymphoblastic leukemic cell line (CCRF-CEM/taxol) was determined2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation.
AID53621The compound was tested for the cytotoxicity against human leukemic DC-3F/ADII cell lines, activity is expressed as IC50 values.1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships.
AID111217In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 9 at an intravenous dose of 16(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID116325In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the increase in lifespan at an intravenous dose of 30(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID57198In vitro 50% inhibition of topoisomerase II mediated k-DNA decatenation1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships.
AID248302Concentration required for growth inhibition of human lung carcinoma cell line (CCRF-CEM) was determined2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation.
AID266299Antiproliferative activity against human A549 cell line2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Potent antitumor 9-anilinoacridines and acridines bearing an alkylating N-mustard residue on the acridine chromophore: synthesis and biological activity.
AID367775Cytotoxicity against human MX1 cells after 72 hrs by SRB assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Novel DNA-directed alkylating agents: design, synthesis and potent antitumor effect of phenyl N-mustard-9-anilinoacridine conjugates via a carbamate or carbonate linker.
AID111218In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 9 at an intravenous dose of 30(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID106083Cytotoxicity against human Breast carcinoma MX-1; Not determined2002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Antitumor AHMA linked to DNA minor groove binding agents: synthesis and biological evaluation.
AID202622The compound was tested for the cytotoxicity against S180 cell lines1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships.
AID367771Cytotoxicity against taxol-resistant human CCRF-CEM cells after 72 hrs by XTT assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Novel DNA-directed alkylating agents: design, synthesis and potent antitumor effect of phenyl N-mustard-9-anilinoacridine conjugates via a carbamate or carbonate linker.
AID41970Cytotoxicity against human nasopharyngeal carcinoma BM-12002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Antitumor AHMA linked to DNA minor groove binding agents: synthesis and biological evaluation.
AID123405In vitro anticancer activity against 4 B6D2F-1 mice bearing P388 leukemia measured by the toxicity death at an intravenous dose of 30(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID248484Concentration required for growth inhibition of human lymphoblastic leukemic cell line (CCRF-CEM) was determined2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation.
AID428404Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT-tetrazolium assay2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Synthesis and in vitro cytotoxicity of 9-anilinoacridines bearing N-mustard residue on both anilino and acridine rings.
AID428406Antitumor activity in human CCRF-CEM cells xenografted mouse at 2 mg/kg, iv qd for 3 days2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Synthesis and in vitro cytotoxicity of 9-anilinoacridines bearing N-mustard residue on both anilino and acridine rings.
AID99086The compound was tested for the cytotoxicity against L1210 cell lines1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships.
AID47003The compound was tested for the cytotoxicity against human leukemic CEM/VBL cell lines1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships.
AID111067In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 11 at an intravenous dose of 22(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID81346Cytotoxicity against human nasopharyngeal carcinoma HONE-12002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Antitumor AHMA linked to DNA minor groove binding agents: synthesis and biological evaluation.
AID266298Antiproliferative activity against human vinblastine resistant CCRF-CEM cell line2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Potent antitumor 9-anilinoacridines and acridines bearing an alkylating N-mustard residue on the acridine chromophore: synthesis and biological activity.
AID111068In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 11 at an intravenous dose of 30(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID367770Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Novel DNA-directed alkylating agents: design, synthesis and potent antitumor effect of phenyl N-mustard-9-anilinoacridine conjugates via a carbamate or carbonate linker.
AID116323In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the increase in lifespan at an intravenous dose of 16(mg/kg).. 1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID86721Cytotoxicity against human hepatoma Hepa-G22002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Antitumor AHMA linked to DNA minor groove binding agents: synthesis and biological evaluation.
AID110724In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average survival time(days) at an intravenous dose of 16(mg/kg).. 1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID111059In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 1 at an intravenous dose of 22(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID110720In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the Average survival time(days) at an intravenous dose of 22(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID367773Ratio of IC50 for taxol-resistant human CCRF-CEM cells to IC50 for human CCRF-CEM cells2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Novel DNA-directed alkylating agents: design, synthesis and potent antitumor effect of phenyl N-mustard-9-anilinoacridine conjugates via a carbamate or carbonate linker.
AID248552Concentration required for growth inhibition of human HCT116 colon tumor cell line (CCRF-CEM); ND = Not determined2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation.
AID123410In vitro anticancer activity against 5 B6D2F-1 mice bearing P388 leukemia measured by the toxicity death at an intravenous dose of 22(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID43838The compound was tested for the cytotoxicity against human leukemic CCRF-CEM cell lines1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships.
AID320266Ratio of Qmax for calf thymus DNA to Q50 for calf thymus DNA2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Synthesis, cytotoxic evaluation, and DNA binding of novel thiazolo[5,4-b]quinoline derivatives.
AID210186In vitro cytotoxicity against human TSGH2002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Antitumor AHMA linked to DNA minor groove binding agents: synthesis and biological evaluation.
AID266297Antiproliferative activity against human taxol resistant CCRF-CEM cell line2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Potent antitumor 9-anilinoacridines and acridines bearing an alkylating N-mustard residue on the acridine chromophore: synthesis and biological activity.
AID43360Cytotoxicity against human T-cell acute lymphocytic leukemia CCRF-CEM2002Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20
Antitumor AHMA linked to DNA minor groove binding agents: synthesis and biological evaluation.
AID111210In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 7 at an intravenous dose of 22(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID111385In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 9 at an intravenous dose of 22(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID47006The compound was tested for the cytotoxicity against human leukemic CEM/VM-1 cell lines1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (16.67)18.2507
2000's10 (83.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.37 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.94 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (8.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]